- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04733755
Beauty Image Efficacy Study
January 27, 2021 updated by: Pharmanex
The objective is to evaluate the effects of oral supplement of a blend containing collagen peptides, phosphatidylserine, Saussurea involucrata and lutein (Beauty Image) on the improvement of skin aging in terms of hydration, gloss, melanin content, roughness and wrinkling, and anti-UV performance.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Nu Skin (China) Daily-use & Health Products CO., LTD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Facial skin with problems of dull, uneven, inelastic, dryness and wrinkle/fine line (At least fit to two problems)
- In general good health and good mental state;
- Willing to read, understand and able to sign the Informed Consent Form;
- Willing to comply with all study protocol requirements.
Exclusion Criteria:
- Intention to become pregnant, pregnant, lactating or within 6 months of delivery;
- Participation in any clinical test or cosmetic product test on skin within 30 days;
- Existence of neurodermatitis, pityriasis, seborrheic dermatitis or psoriasis capitis on test area;
- Use of any anti-inflammatory drugs in the past 2 months;
- A history of skin diseases such as psoriasis, eczema, psoriasis, skin cancer, etc.;
- IDDM: Insulin dependent diabetic patients;
- Current treatment for asthma or other chronic respiratory diseases;
- Undergoing anticancer chemotherapy in the past 6 months;
- Existence of any other health problems or chronic diseases;
- Use of retinoids, alpha hydroxyl acid, ortho-hydroxybenzoic acid, hydroquinone nearly within 3 months; or use of prescriptions (such as antibiotics, retinoids, alpha hydroxyl acid or steroids), oral contraceptives (Use of same contraceptives for 6 months excepted);
- Existence of the following conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results, including, but not limited to, diabetes, vascular disease, hepatitis, eczema, psoriasis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Beauty Image
|
1.97g/package; 2 packages one day for 8 weeks
|
|
PLACEBO_COMPARATOR: Placebo Control
|
Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in facial photo from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8
|
Facial Photo Capture by VISIA-CR CR (CANFIELD, America).
The instrument captured all-face skin under different light sources about the Standard 1, Standard 2, UV light, Parallel-polarized light and Cross-polarized light source with left, front and right sides design.
|
Baseline, Week 4 and Week 8
|
|
Change in skin roughness from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8
|
Skin Roughness: VisioScan VC98 (Courage & Khazaka, Germany).
The instrument consists of a special b/w video sensor chip with very high resolution, an objective and a ring shaped UVA-light source in a small, easy-to-handle, ergonomically designed plastic casing.
The parameter of SEr (skin roughness) was analyzed in this study.
|
Baseline, Week 4 and Week 8
|
|
Change in skin wrinkle from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Skin Wrinkle: VisioScan VC98 (Courage & Khazaka, Germany) The instrument consists of a special b/w video sensor chip with very high resolution, an objective and a ring shaped UVA-light source in a small, easy-to-handle, ergonomically designed plastic casing.
The parameter of SEw (wrinkles) was analyzed in this study.
|
Baseline, Week 4 and Week 8.
|
|
Change in skin color from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8
|
Skin Color of L, a, b and ITA: Spectrophotometer CM2600d (Konica Minolta, Japan) The Minolta spectrophotometer (Konica Minolta, CM2600d) is generally used to measure and carry out quality control of the color of an object.
This instrument allows measurement in the modes of specular component included (SCI) and specular component excluded (SCE).
As indicated by the description, SCI includes the specular reflection while SCE excludes the specular reflection from measured surface.
The parameters of L, a, b value under SCE light source were recorded and the ITA value were calculated in this study.
|
Baseline, Week 4 and Week 8
|
|
Change in melanin content from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8
|
Melanin Content: Mexameter MX18 (Courage & Khazaka, Germany) The measurement is based on absorption/reflection.
The probe of the Mexameter® MX 18 emits 3 specific light wavelengths.
A receiver measures the light reflected by the skin.
As the quantity of emitted light is defined, the quantity of light absorbed by the skin can be calculated.
The melanin is measured by specific wavelengths chosen to correspond to different absorption rates by the pigments.
For the erythema measurement specific wavelengths are also used, corresponding to the spectral absorption peak of haemoglobin and to avoid other color influences.
|
Baseline, Week 4 and Week 8
|
|
Change in skin gloss from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Skin Gloss: Glossymeter GL200 (Courage & Khazaka, Germany) The probe sends out white LED light, arranged circularly to uniformly illuminate the skin.
The emitted light is scattered in all directions, some parts travel through the layers and some is scattered out of the skin.
The light reflected from the skin is measured in the probe.
The raw data of the probe are corrected with a special color matrix to adapt them closely to standard values and are expressed accordingly.
|
Baseline, Week 4 and Week 8.
|
|
Change in skin hydration from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Skin Hydration: Corneometer CM825 (Courage & Khazaka, Germany) It measures moisture content of the skin via capacitance measurements.
The measurable capacitance is proportional to the water content of stratum corneum, given that other physical and physiological variables affecting skin electrical properties are carefully controlled.
|
Baseline, Week 4 and Week 8.
|
|
Change in transepidermal water Loss from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Transepidermal Water Loss (TEWL): Vapometer (Delfin Technologies, Finland) It's equipped with a closed cylindrical chamber.
When it is in contact with the skin, the relative humidity (RH %) in the chamber increases, based on which transepidermal water loss (TEWL) is calculated.
Lower TEWL means better skin barrier function.
Vapometer measurement will be done at the tested areas on face skin.
|
Baseline, Week 4 and Week 8.
|
|
Change in skin elasticity from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Skin Elasticity: Cutometer dual MPA580 (Courage & Khazaka, Germany) The Cutometer® is destined to measure elasticity of the upper skin layer using negative pressure which deforms the skin mechanically.
|
Baseline, Week 4 and Week 8.
|
|
Change in anti-ultraviolet from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
Evaluation of Anti-ultraviolet
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of skin tone dullness from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of skin tone dullness was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of skin tone unevenness from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of skin tone unevenness was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of skin dryness from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of skin dryness was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of skin inelastic from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of skin inelastic was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of wrinkle/fine line from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of wrinkle/fine line was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Change in dermatologist grading of skin roughness from baseline at week 4 and week 8
Time Frame: Baseline, Week 4 and Week 8.
|
The skin parameter of skin roughness was assessed through '0 to 5' scales
|
Baseline, Week 4 and Week 8.
|
|
Self Assessment
Time Frame: Baseline, Week 1, Week 2, Week 4 and Week 8.
|
A self assessment questionnaire about skin conditions improvement was answered by each subject
|
Baseline, Week 1, Week 2, Week 4 and Week 8.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2018
Primary Completion (ACTUAL)
August 1, 2018
Study Completion (ACTUAL)
September 1, 2018
Study Registration Dates
First Submitted
January 27, 2021
First Submitted That Met QC Criteria
January 27, 2021
First Posted (ACTUAL)
February 2, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 2, 2021
Last Update Submitted That Met QC Criteria
January 27, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- C180201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Aging
-
Mert ErsanNot yet recruitingSkin Aging | Skin Quality | Facial Aging
-
Amazentis SAproDERM GmbHCompleted
-
IAS Skin CareNot yet recruitingSkin Aging | Transepidermal Water Loss | Skin Hydration | Facial AgingUnited States
-
ChinaNormCompletedMenopause | Skin Aging | Genetic Factors | Reproductive AgingChina
-
AB Biotics, SADr. Goya Análisis, SL.Not yet recruitingSkin | Face Skin Photoaging | Fine Lines | Face Aging/Photo Aging of Moderate Grade | Skin Ageing
-
Iluminage Ltd.Unknown
-
Adriana Clemente MendonçaCompletedSkin Aging | Skin RejuvenationBrazil
-
i+Med S.Coop.Completed
-
i+Med S.Coop.Completed
-
Mesoestetic Pharma Group S.L.CompletedSkin Aging | Skin WrinklingBulgaria
Clinical Trials on Beauty Image
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedBreast CancerFrance
-
PharmanexCompletedSkin Elasticity | Beauty Drink Powder | Cosmetic Apparatus on Skin | Skin Dryness | Skin Moisture | Skin Evenness | Skin FirmnessChina
-
NovoBliss Research Pvt LtdVasu Healthcare Private LimitedCompletedHealthy | Wrinkle | Skin Pigment | Dry SkinIndia
-
University of Sao PauloCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Recruiting
-
Masonic Cancer Center, University of MinnesotaWithdrawnMucopolysaccharidosis Type IH | Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome) | MPS IH, Hurler Syndrome
-
Radboud University Medical CenterUniversity of Vienna; University of AmsterdamCompletedYoung Adults | Sensory Processing SensitivityNetherlands
-
Casa Colina Hospital and Centers for HealthcareCompletedMultiple Sclerosis | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Graves Disease | Myasthenia Gravis | Traumatic Brain Injury | Stroke, Ischemic | Stroke, Acute | Stroke Hemorrhagic | SCI - Spinal Cord Injury | Guillain-Barre Syndrome | Lupus Erythematosus | Stroke (CVA) or TIA | Ehlers-Danlos Syndromes...United States
-
San Gallicano Dermatological Institute IRCCSNot yet recruitingVulvar Lichen Sclerosus | Vulvar Atrophy
-
Chung Shan Medical UniversityCompleted
-
Galderma R&DDeNova ResearchCompletedInjection Site DiscomfortUnited States